Abstract:Genome-wide association studies have discovered numerous common variants associated with human cancers. However, the contribution of exome-wide rare variants to cancers remains largely unexplored, especially for the protein-coding variants. The UK Biobank provides detailed cancer follow-up information linked to whole-exome sequencing (WES) for approximately 450,000 participants, offering an unprecedented opportunity to evaluate the effect of exome variation on pan-cancer. Here, we performed exome-wide association studies (ExWAS) based on single variant levels and gene levels to detect their associations across 20 primary cancer types in the discovery set (WES-300k, N = 284,456) and replication set (WES-150k, N = 143,478), separately. The ExWAS detected 143 independent variants at variant-level and 49 genes at gene-level, while nine variants and eight genes were shared across cancers. In the cross-trait meta-analysis, we identified 239 additional independent pleiotropic variants, mapping to the genes which were functional through trans-omics analyses in transcriptomics and proteomics. Further, we developed exome-wide risk scores (ERS) to identify high-risk populations based on rare variants with minor allele frequency (MAF) < 0.05. The ERS had satisfactory performance in cancer risk stratification, especially for the extremely high-risk persons (top 5% ERS) that were frequently risk allele carriers. The ERS (median C-index (IQR): 0.655 (0.636-0.667)) outperforms the traditional polygenic risk score (PRS) (median C-index (IQR): 0.585 (0.572-0.614)) for discrimination in the replication set. Our findings offer further insight into the genetic architecture of human exomes for cancer susceptibility. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by the National Natural Science Foundation of China (82103946 to S.S., 82173620 to Y.Z., 81530088 to F.C.), National Key Research and Development Program of China (2016YFE0204900 to F.C.), Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJB330004 to S.S.). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes UK Biobank data is available from <https://www.ukbiobank.ac.uk/>. TCGA data is available from <https://portal.gdc.cancer.gov/>. GTEx data is available from <https://www.gtexportal.org/home/>. CPTAC data is available from <https://pdc.esacinc.com/pdc/pdc>.

Enhancing Variant Calling in Whole-Exome Sequencing Data Using Population-Matched Reference Genomes.

Enhancing Variant Calling in Whole Exome Sequencing (WES) Data Using Population-Matched Reference Genomes

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Whole Genome and Exome Sequencing Reference Datasets from a Multi-Center and Cross-Platform Benchmark Study

A review of consensus statements, practice resources, standards and guidelines for clinical applications of next-generation sequencing technologies in the United States

T2T-YAO: A Telomere-to-telomere Assembled Diploid Reference Genome for Han Chinese

Using Off-Target Data from Whole-Exome Sequencing to Improve Genotyping Accuracy, Association Analysis and Polygenic Risk Prediction.

Unveiling novel genetic variants in 370 challenging medically relevant genes using the long read sequencing data of 41 samples from 19 global populations

One Size Doesn't Fit All - RefEditor: Building Personalized Diploid Reference Genome to Improve Read Mapping and Genotype Calling in Next Generation Sequencing Studies.

Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing

Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing

An evaluation of copy number variation detection tools from whole-exome sequencing data.

Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage

Exome-wide association studies discover germline mutation patterns and identify high-risk populations in human cancers

Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders

The benefit of a complete reference genome for cancer structural variant analysis

A Three-Caller Pipeline for Variant Analysis of Cancer Whole-Exome Sequencing Data

Cancer whole-genome sequencing: present and future

Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

Comparison of Somatic Mutation Landscapes in Chinese Versus European Breast Cancer Patients